International Clinical Trial: Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-04)

Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07816315) titled 'Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-04)' on Sept. 7.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).

Primary Sponsor: Ollin Biosciences, Inc.

Condition: Wet Age Related Macular Degeneration

Intervention: Drug: OLN324

Recruitment Status: Not recruiting

Phase: Phase 3

Date of First Enrollment: October 15, 2026

Target Sample Size: 500

To know more, visit h...